Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2

被引:0
|
作者
Kiarie, Irene Wanjiru [1 ,2 ]
Hoffka, Gyula [1 ,2 ]
Laporte, Manon [3 ]
Leyssen, Pieter [3 ,4 ]
Neyts, Johan [3 ,4 ]
Tozser, Jozsef [1 ]
Mahdi, Mohamed [1 ]
机构
[1] Univ Debrecen, Fac Med, Dept Biochem & Mol Biol, Lab Retroviral Biochem, H-4032 Debrecen, Hungary
[2] Univ Debrecen, Doctoral Sch Mol Cell & Immune Biol, H-4032 Debrecen, Hungary
[3] Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol Immunol & Transplantat, Lab Virol & Chemotherapy, B-3000 Leuven, Belgium
[4] European Res Infrastruct Highly Pathogen Agents ER, Rue Trone 98, B-1050 Brussels, Belgium
来源
VIRUSES-BASEL | 2024年 / 16卷 / 10期
关键词
HIV-2; integrase strand transfer inhibitor (INSTIs); HIV; integrase; lenacapavir; SARS-CoV-2; PHENOTYPIC SUSCEPTIBILITY; DRUG-RESISTANCE; VIRUS; DOLUTEGRAVIR; ETRAVIRINE; ACCURACY; PROTEASE; OUTCOMES; DOCKING; BIOLOGY;
D O I
10.3390/v16101607
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase. The viral capsid plays an important role during the viral life cycle, including nuclear importation in the case of lentiviruses and integration targeting events; hence, targeting the integrase and the viral capsid is a favorable therapeutic strategy. While integrase strand transfer inhibitors (INSTIs) are recommended as first-line regimens given their high efficacy and tolerability, lenacapavir is the first capsid inhibitor and the newest addition to the HIV treatment arsenal. These inhibitors are however designed for treatment of HIV-1 infection, and their efficacy against HIV-2 remains widely understudied and inconclusive, supported only by a few limited phenotypic susceptibility studies. We therefore carried out inhibition profiling of a panel of second-generation INSTIs and lenacapavir against HIV-2 in cell culture, utilizing pseudovirion inhibition profiling assays. Our results show that the tested INSTIs and lenacapavir exerted excellent efficacy against ROD-based HIV-2 integrase. We further evaluated the efficacy of raltegravir and other INSTIs against different variants of SARS-CoV-2; however, contrary to previous in silico findings, the inhibitors did not demonstrate significant antiviral activity.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Integrase strand transfer inhibitors in the treatment of HIV-2 infection: report of 39 patients
    Sequeira, Filipa
    Grazina, Sara
    Alves, Joao
    Peres, Susana
    Borges, Fernando
    Miranda, Ana Claudia
    Aldir, Isabel
    Mansinho, Kamal
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [2] Clinical Outcomes of Integrase Strand Transfer Inhibitors Containing Antiretroviral Therapy in HIV-2: A Narrative Review
    Boschloo, Wendy J.
    van Welzen, Berend J.
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (06) : 1161 - 1175
  • [3] Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main protease
    Mohamed Mahdi
    János András Mótyán
    Zsófia Ilona Szojka
    Mária Golda
    Márió Miczi
    József Tőzsér
    Virology Journal, 17
  • [4] Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main protease
    Mahdi, Mohamed
    Motyan, Janos Andras
    Szojka, Zsofia Ilona
    Golda, Maria
    Miczi, Mario
    Tozser, Jozsef
    VIROLOGY JOURNAL, 2020, 17 (01)
  • [5] Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants
    Smith, Robert A.
    Raugi, Dana N.
    Wu, Vincent H.
    Zavala, Christopher G.
    Song, Jennifer
    Diallo, Khardiata Mbaye
    Seydi, Moussa
    Gottlieb, Geoffrey S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (05)
  • [6] In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
    Smith, Robert A.
    Raugi, Dana N.
    Pan, Charlotte
    Sow, Papa Salif
    Seydi, Moussa
    Mullins, James I.
    Gottlieb, Geoffrey S.
    RETROVIROLOGY, 2015, 12
  • [7] In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
    Robert A Smith
    Dana N Raugi
    Charlotte Pan
    Papa Salif Sow
    Moussa Seydi
    James I Mullins
    Geoffrey S Gottlieb
    Retrovirology, 12
  • [8] CFTR Inhibitors Display In Vitro Antiviral Activity against SARS-CoV-2
    Lagni, Anna
    Lotti, Virginia
    Diani, Erica
    Rossini, Giada
    Concia, Ercole
    Sorio, Claudio
    Gibellini, Davide
    CELLS, 2023, 12 (05)
  • [9] No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands
    Verburgh, Myrthe L.
    van der Valk, Marc
    Rijnders, Bart J. A.
    Reiss, Peter
    Wit, Ferdinand W. N. M.
    AIDS, 2023, 37 (09) : 1481 - 1486
  • [10] Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro
    Ma, Ling
    Li, Quanjie
    Xie, Yongli
    Zhao, Jianyuan
    Yi, Dongrong
    Guo, Saisai
    Guo, Fei
    Wang, Jing
    Yang, Long
    Cen, Shan
    ANTIVIRAL RESEARCH, 2022, 207